Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
about
Etrolizumab for induction of remission in ulcerative colitisThe impact of biological interventions for ulcerative colitis on health-related quality of lifeEtrolizumab for induction of remission in ulcerative colitisAnti-MAdCAM antibody for induction of remission in ulcerative colitisInflammatory bowel disease surgery in the biologic eraCurrent approaches for optimizing the benefit of biologic therapy in ulcerative colitisHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesReview article: the role of anti-TNF in the management of ulcerative colitis -- past, present and futureInfliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysisSystematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitisBiologics in inflammatory bowel disease: what are the data?Golimumab for the treatment of ulcerative colitis.Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel diseaseUtilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.Introducing vedolizumab to clinical practice: who, when, and how?Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis.Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World DataMucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.Overview of cancer vaccines: considerations for development.Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisEarly Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study.Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.Protective Effect of Daikenchuto on Dextran Sulfate Sodium-Induced Colitis in Mice.
P2860
Q24186788-1CAA23C8-4F58-404C-8D6F-1D090CE735F8Q24187078-C3818A29-1A58-4E38-9205-8223780BB70CQ24187269-F2526C3C-5E91-4699-A031-EE1DF2407BB1Q24187593-ED6F5BED-DE24-4632-B57E-D47E20B8C18EQ26745627-F5D3B8C0-C525-47DA-97D6-1D1320F6A15BQ26745712-F10C692B-0EDD-4920-9FB7-D66BD85E0B63Q26777409-B9DF39F2-FDD7-47C3-B6BB-61DBFA6A552BQ26798299-1077AFBC-FF5A-402E-8CA7-D915E2801F34Q26823221-DAD94E31-41ED-421C-94F2-0653C2D185FCQ26866940-5A2C8ED9-7C51-4641-9140-6B8B321E224BQ26991673-8E22722B-A1E5-474F-87A4-40D9F8E0D937Q26992012-9F92B587-0512-44BF-B81B-AA9626134EB4Q27006683-996DAF09-2ABE-4BC8-AF3D-AA75DF8F9BFCQ28088683-6DBE124D-74C9-4D23-8CDE-0D6E5CD97D72Q31017419-BEFC74ED-F380-4CEB-B556-B8929FA101EDQ33852257-1711E879-1FD3-4008-AE70-C6B5BDD8D7F7Q33865593-870E0D50-93BD-44AA-A918-96F374D847B5Q34489872-BC90DADC-03D3-4917-8E24-3E0A2536C301Q34528270-DE85C745-4961-4443-B41B-AC0CED5D485CQ34635522-BAAD80B7-1D7A-4653-A4AE-58E03C2267CEQ34779205-1D7FFA80-60BC-46CB-A740-D89E663F8791Q35100867-180AD3CA-68ED-4347-BDE1-6C972A80AE27Q35188609-65131E41-283F-41F2-8F23-BA2C3C3ED4FCQ35526652-65A92626-5972-49C8-ADA6-AFD8A9B86312Q35562290-6267331C-53A1-4375-BF86-E93ABFA342E6Q35645531-0EA7546B-046D-4BB3-847A-AECEA1E8DD1AQ35778820-9F7F47C5-D2AD-4457-8A86-C79566597D4DQ35937632-BF06D70E-9D8C-479B-87E8-8F4416AE531FQ36578893-174B46BE-E61A-422F-A00C-FD72EE02D754Q36584389-404E9639-B6A4-405C-B9EE-043C35581536Q36631339-5ED5B0BB-1D1A-46DD-9190-F1FB1F2E6B33Q36882311-DCC6B86E-9C36-4961-A30F-DD0A2599254FQ37089289-06D4F009-5DB4-4A05-8A0F-2ED49C255246Q37308977-FB12DABE-7532-4B01-96D6-DDEC92752DCBQ37342575-B29052A2-F538-4262-94C8-CE057BFA08F1Q37411301-F3B0E565-B1F5-4264-AF96-EEAC22FF154EQ37585946-C86688E6-A986-4CB1-8791-1F2FDE3B28D0Q37600339-3A9C3F6D-BBC6-4E80-A0D4-3C52F1F99495Q37624487-98907C06-A1C1-41DF-A2EE-64BE5CD6D109Q37624817-8FBE413A-02CE-47D4-B7F7-0F98155F18E4
P2860
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
description
im Januar 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 05 January 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2011
@uk
name
Adalimumab for induction of cl ...... a randomised controlled trial
@en
Adalimumab for induction of cl ...... a randomised controlled trial
@nl
type
label
Adalimumab for induction of cl ...... a randomised controlled trial
@en
Adalimumab for induction of cl ...... a randomised controlled trial
@nl
prefLabel
Adalimumab for induction of cl ...... a randomised controlled trial
@en
Adalimumab for induction of cl ...... a randomised controlled trial
@nl
P2093
P356
P1433
P1476
Adalimumab for induction of cl ...... a randomised controlled trial
@en
P2093
Andreas Lazar
Bidan Huang
Daniel W Hommes
Geert D'Haens
Mary Beth Tighe
Remo Panaccione
Roopal Thakkar
Stefan Schreiber
Stephen Hanauer
Walter Reinisch
P304
P356
10.1136/GUT.2010.221127
P407
P577
2011-01-05T00:00:00Z